Skip to main content
Clinical Trials/NCT01764802
NCT01764802
Completed
Phase 2

Psychosexual Intervention for Gynecologic and Breast Cancer Patients

Ohio State University Comprehensive Cancer Center1 site in 1 country100 target enrollmentOctober 2010
ConditionsOvarian SarcomaOvarian Stromal CancerStage I Uterine SarcomaStage I Vaginal CancerStage I Vulvar CancerStage IA Cervical CancerStage IA Endometrial CarcinomaStage IA Fallopian Tube CancerStage IA Ovarian Epithelial CancerStage IA Ovarian Germ Cell TumorStage IA Primary Peritoneal Cavity CancerStage IB Cervical CancerStage IB Endometrial CarcinomaStage IB Fallopian Tube CancerStage IB Ovarian Epithelial CancerStage IB Ovarian Germ Cell TumorStage IB Primary Peritoneal Cavity CancerStage IC Fallopian Tube CancerStage IC Ovarian Epithelial CancerStage IC Ovarian Germ Cell TumorStage IC Primary Peritoneal Cavity CancerStage II Endometrial CarcinomaStage II Gestational Trophoblastic TumorStage II Uterine SarcomaStage II Vaginal CancerStage II Vulvar CancerStage IIA Cervical CancerStage IIA Fallopian Tube CancerStage IIA Ovarian Epithelial CancerStage IIA Ovarian Germ Cell TumorStage IIA Primary Peritoneal Cavity CancerStage IIB Cervical CancerStage IIB Fallopian Tube CancerStage IIB Ovarian Epithelial CancerStage IIB Ovarian Germ Cell TumorStage IIB Primary Peritoneal Cavity CancerStage IIC Fallopian Tube CancerStage IIC Ovarian Epithelial CancerStage IIC Ovarian Germ Cell TumorStage IIC Primary Peritoneal Cavity CancerStage III Gestational Trophoblastic TumorStage III Uterine SarcomaStage III Vaginal CancerStage III Vulvar CancerStage IIIA Cervical CancerStage IIIA Endometrial CarcinomaStage IIIA Fallopian Tube CancerStage IIIA Ovarian Epithelial CancerStage IIIA Ovarian Germ Cell TumorStage IIIA Primary Peritoneal Cavity CancerStage IIIB Cervical CancerStage IIIB Endometrial CarcinomaStage IIIB Fallopian Tube CancerStage IIIB Ovarian Epithelial CancerStage IIIB Ovarian Germ Cell TumorStage IIIB Primary Peritoneal Cavity CancerStage IIIC Endometrial CarcinomaStage IIIC Fallopian Tube CancerStage IIIC Ovarian Epithelial CancerStage IIIC Ovarian Germ Cell TumorStage IIIC Primary Peritoneal Cavity CancerBreast Cancer

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Ovarian Sarcoma
Sponsor
Ohio State University Comprehensive Cancer Center
Enrollment
100
Locations
1
Primary Endpoint
Sexual satisfaction graded using the global evaluation from the Derogatis Sexual Function Inventory (DSFI)
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

This randomized phase II trial studies how well psychosexual intervention works in patients with stage I-III gynecologic or breast cancer. Psychosexual intervention may improve sexual and psychosocial function.

Detailed Description

PRIMARY OBJECTIVES: I. Efficacy for reducing the severity of sexual distress, difficulty, and dysfunction in a phase II randomized clinical trial (RCT). OUTLINE: Patients are randomized to 1 of 2 arms. ARM I (Enhanced standard care): Patients participate in enhanced standard care intervention comprising stress reduction, information delivery regarding gynecologic or breast cancer treatments and sexuality, and provision of a survivorship care plan (SCP) created using OncoLink over 1 hour following baseline assessment and before 6 months. ARM II (Psychological intervention): Patients participate in individual or group therapy over 1.5 hours weekly for 4 weeks, bi-weekly for 8 weeks, and monthly for 2 months and complete assessment interviews. After completion of study treatment, patients are followed up at 3, 6, and 9 months.

Registry
clinicaltrials.gov
Start Date
October 2010
End Date
June 1, 2017
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Kristen Carpenter

Principal Investigator

Ohio State University Comprehensive Cancer Center

Eligibility Criteria

Inclusion Criteria

  • Stage I-III gynecologic (any site) or breast cancer
  • Able to speak/read English
  • Able to give informed consent

Exclusion Criteria

  • Prior non-gynecologic/breast cancer diagnosis
  • Refusal of any cancer treatment(s)
  • Non-ambulatory
  • Concurrent diagnosis of organic brain syndrome, dementia, mental retardation, or significant sensory deficit
  • Major mental illness (e.g, schizophrenia, major depressive disorder)
  • Current/recent (prior 12 months) pregnancy
  • Residence \> 70 miles from research site

Outcomes

Primary Outcomes

Sexual satisfaction graded using the global evaluation from the Derogatis Sexual Function Inventory (DSFI)

Time Frame: Up to 2 months

95% confidence intervals will be obtained.

Sexual distress graded using the female Sexual Distress Scale (FSDS)

Time Frame: Up to 4 weeks

The Likert scale will be used. 95% confidence intervals will be obtained.

Sexual behavior/repertoire (kissing, intercourse, etc.) graded using the Sexual Experiences Scale (SES)

Time Frame: Up to 2 months

Multilevel modeling will be used to model time effects compared to repeated-measures analysis of variance (ANOVA) because it allows not only fitting different patterns of average change (i.e., linear, quadratic), but also estimates individual variability in the rate of change. Both linear and quadratic change models will be tested and an optimal model will be determined. 95% confidence intervals will be obtained.

Sexual responsiveness (desire, arousal, orgasm) using the Female Sexual Functioning Index (FSFI)

Time Frame: Up to 4 weeks

Principal components analysis yields six subscales: desire, arousal, lubrication, orgasm, satisfaction, and pain. Items are rated using the Likert scales. 95% confidence intervals will be obtained.

Sexual pain graded using the International Pelvic Pain Society Pelvic Pain Assessment, patient/physician version

Time Frame: Up to 9 months

Secondary Outcomes

  • Health-related quality of life graded according to the RAND Medical Outcomes Study, Short-form 12 (SF-12)(Up to 9 months)
  • Emotional distress graded using the Profile of Mood States (POMS)(Up to 9 months)
  • Depressive symptoms graded using the Center for Epidemiologic Studies Depression Scale (CES-D)(Up to 9 months)
  • Cancer-related stress graded according to the Impact of Events Scale-Revised (IES-R)(Up to 9 months)
  • Body change stress graded according to the Impact of Treatment Scale (ITS)(Up to 9 months)

Study Sites (1)

Loading locations...

Similar Trials